Granules India’s stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the company’s product pipeline and business stabilisation. The company anticipates better growth in FY27. Approvals for six products in Europe are awaited. Granules focuses on CNS, ADHD, and oncology products. The Gagillapur facility remediation is progressing well with US FDA.
Jio IPO’s GMP rises to 22% as India’s largest ever issue set to open on October 21. Should you subscribe?
The IPO is priced at Rs 1,065-1,119 per share and will open on October 21, closing on October 23. At the upper end of the